Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12285–12292 | Cite as

Report of clinical studies on chronochemotherapy for advanced non-small cell lung cancer in China

  • Mei Ji
  • Xiao-Dong Li
  • Hanze Zhang
  • Zhong-Hua Ning
  • Xiaofei Zhang
  • Wei-Qing Zhao
  • Li-Na Zhu
  • Jie Li
  • Chang-Ping Wu
Research Article

Abstract

Chronochemotherapy has been proposed as a promising modality to provide timely optimized medication to achieve maximum efficacy with minimum side effect for patients with non-small cell lung cancer for years. We collected the data of 11 clinical studies performed in China with the purpose to compare the difference between chronochemotherapy and traditional chemotherapy. Results showed that chronochemotherapy has a more favorable efficacy and safety than traditional chemotherapy.

Keywords

Non-small cell lung cancer Chronochemotherapy Clinical studies China 

Notes

Acknowledgments

This study was supported by a grant from the Jiangsu Health International Exchange Supporting Program (to Dr. Xiao-Dong Li).

Conflicts of interest

None

References

  1. 1.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase iii trial. Lung Cancer. 2006;52:155–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Non small cell lung cancer. 2013, cited 2013-10-30. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.Pdf.
  5. 5.
    Nation Comprehensive Cancer Network (2013) non–small cell lung cancer (version 2.2014). Available: http://www.nccn.org/professionals/physician_gls/pdf/nscl.Pdf Accessed 21 Jan 2014.
  6. 6.
    Azzoli CG, Temin S, Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Oncol Pract/Am Soc Clin Oncol. 2012;8:63–6.CrossRefGoogle Scholar
  7. 7.
    Azzoli CG, Giaccone G, Temin S. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Oncol Pract/Am Soc Clin Oncol. 2010;6:39–43.CrossRefGoogle Scholar
  8. 8.
    D’Addario G, Felip E, Group EGW. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2009;20 Suppl 4:68–70.Google Scholar
  9. 9.
    Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122–33.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9:886–96.PubMedCrossRefGoogle Scholar
  11. 11.
    Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377–421.PubMedCrossRefGoogle Scholar
  12. 12.
    Levi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control: CCC. 2006;17:611–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Halberg F, Haus E, Cardoso SS, Scheving LE, Kuhl JF, Shiotsuka R, et al. Toward a chronochemotherapy of neoplasia: tolerance of treatment depends upon host rhythms. Experientia. 1973;29:909–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. International journal of cancer Journal international du cancer. 1997;70:241–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang XL, Fu CJ, Bu RF. Role of circadian clocks in the development and therapeutics of cancer. J Int Med Res. 2011;39:2061–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Takimoto CH. Chronomodulated chemotherapy for colorectal cancer: failing the test of time? Eur J Cancer. 2006;42:574–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Mormont MC, Levi F. Cancer chronochemotherapy: principles, applications, and perspectives. Cancer. 2003;97:155–69.PubMedCrossRefGoogle Scholar
  18. 18.
    Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593–628.PubMedCrossRefGoogle Scholar
  19. 19.
    Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86:1608–17.PubMedCrossRefGoogle Scholar
  20. 20.
    Focan C, Denis B, Kreutz F, Focan-Henrard D, Levi F. Ambulatory chronochemotherapy with 5-fluorouracil, folinic acid, and carboplatin for advanced non-small cell lung cancer. A phase ii feasibility trial. J Infus Chemother. 1995;5:148–52.PubMedGoogle Scholar
  21. 21.
    Vincenzi B, Santini D, La Cesa A, Tonini G. Cancer chronochemotherapy: principles, applications, and perspectives. Cancer. 2003;98:881–2. author reply 882–883.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Mei Ji
    • 1
  • Xiao-Dong Li
    • 1
  • Hanze Zhang
    • 2
  • Zhong-Hua Ning
    • 3
  • Xiaofei Zhang
    • 4
  • Wei-Qing Zhao
    • 1
  • Li-Na Zhu
    • 1
  • Jie Li
    • 5
  • Chang-Ping Wu
    • 1
    • 6
  1. 1.Department of OncologyThe Third Affiliated Hospital of Soochow UniversityChangzhouChina
  2. 2.Department of Epidemiology and BiostatisticsCollege of Public Health, University of South FloridaTampaUSA
  3. 3.Department of Radiation OncologyThe Third Affiliated Hospital of Soochow UniversityChangzhouChina
  4. 4.Department of Clinical Oncology, Institute of Development, Aging and CancerTohoku UniversitySendaiJapan
  5. 5.Department of PharmacyThe Third Affiliated Hospital of Soochow UniversityChangzhouChina
  6. 6.Department of Tumor Biological TreatmentThe Third Affiliated Hospital of Soochow UniversityChangzhouChina

Personalised recommendations